The longitudinal trajectory of emotional cognition in subgroups of recently diagnosed patients with bipolar disorder

Imagem de Miniatura
Arquivos
art_ROTENBERG_The_longitudinal_trajectory_of_emotional_cognition_in_subgroups_2023.PDF (1.17 MB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Autores
KJAERSTAD, Hanne Lie
VARO, Cristina
VINBERG, Maj
KESSING, Lars Vedel
MISKOWIAK, Kamilla Woznica
Citação
EUROPEAN NEUROPSYCHOPHARMACOLOGY, v.71, p.9-24, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Although cross-sectional studies show heterogeneity in emotional cognition in bipolar disorder (BD), the temporal course within subgroups is unclear. In this prospective, longitudinal study we assessed the trajectories of emotional cognition subgroups within a 16-month follow-up pe-riod in recently diagnosed BD patients compared to healthy controls (HC). Recently diagnosed BD patients and HC underwent comprehensive emotional and non-emotional testing at base-line and again at follow-up. We employed hierarchical cluster analysis at baseline to identify homogenous emotional cognition subgroups of patients, and changes across the subgroups of BD and HC were assessed with linear mixed-model analyses. We found two emotional cogni-tion subgroups: subgroup 1 (65%, n = 179), showing heightened negative emotional reactivity in neutral and negative social scenarios and faster recognition of emotional facial expressions than HC (ps< 0.001, n = 190), and subgroup 2 (35%, n = 96) showing blunted reactivity in pos-itive social scenarios, impaired emotion regulation, poorer recognition of positive and slower recognition of all facial expressions than HC (ps <=.03). Subgroup 1 exhibited normalization of the initial emotional cognition abnormalities in follow-up. In contrast, subgroup 2 showed a lack of improvement in reactivity positively-valenced emotional information. Patients in sub-group 2 presented more and longer mixed episodes during the follow-up time and were more often prescribed lithium. One third of patients display blunted emotional reactivity, impaired emotion regulation abilities and facial expression recognition difficulties also show persistent impairments and poorer course of illness. This subgroup may indicate a need for earlier and more targeted therapeutic interventions. (c) 2023 The Author(s).
Palavras-chave
Bipolar disorder, Emotional cognition, Longitudinal, Cluster analysis, Emotion regulation
URI
https://observatorio.fm.usp.br/handle/OPI/54030
Referências
  1. Army Individual Test Battery, 1944, MAN DIR SCOR
  2. Baune BT, 2015, BIPOLAR DISORD, V17, P41, DOI 10.1111/bdi.12341
  3. Bekele E, 2017, IEEE T NEUR SYS REH, V25, P739, DOI 10.1109/TNSRE.2016.2591556
  4. Bonnin CM, 2018, J AFFECT DISORDERS, V240, P57, DOI 10.1016/j.jad.2018.07.045
  5. Bora E, 2016, EUR NEUROPSYCHOPHARM, V26, P1338, DOI 10.1016/j.euroneuro.2016.04.002
  6. Bourne C, 2013, ACTA PSYCHIAT SCAND, V128, P149, DOI 10.1111/acps.12133
  7. Burdick KE, 2014, PSYCHOL MED, V44, P3083, DOI 10.1017/S0033291714000439
  8. Cardoso T, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0605-x
  9. Cha HS, 2020, IEEE ACCESS, V8, P62065, DOI 10.1109/ACCESS.2020.2983608
  10. Cohen JN, 2017, BEHAV THER, V48, P820, DOI 10.1016/j.beth.2017.07.003
  11. Colom F, 2005, EUR PSYCHIAT, V20, P359, DOI 10.1016/j.eurpsy.2005.06.002
  12. Corwin J, 1994, NEUROPSYCHOLOGY, V8, P110, DOI 10.1037/0894-4105.8.1.110
  13. de Siqueira Rotenberg L., 2022, BRAZ J MED BIOL RES
  14. Ehrlich TJ, 2022, ACTA PSYCHIAT SCAND, V146, P240, DOI 10.1111/acps.13460
  15. Gruber J, 2014, EMOTION, V14, P388, DOI 10.1037/a0035249
  16. Haffner P, 2018, CLIN PSYCHOL PSYCHOT, V25, P50, DOI 10.1002/cpp.2124
  17. HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278
  18. Harmer CJ, 2009, AM J PSYCHIAT, V166, P1178, DOI 10.1176/appi.ajp.2009.09020149
  19. Harmer CJ, 2004, AM J PSYCHIAT, V161, P1256, DOI 10.1176/appi.ajp.161.7.1256
  20. Hogenelst K, 2015, SOC NEUROSCI-UK, V10, P219, DOI 10.1080/17470919.2014.994786
  21. Keramatian K, 2021, DIALOGUES CLIN NEURO, V23, P29, DOI 10.1080/19585969.2022.2042164
  22. Kessing LV, 2017, ACTA PSYCHIAT SCAND, V135, P51, DOI 10.1111/acps.12667
  23. Kessing LV, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015462
  24. Kessing LV, 2013, BRIT J PSYCHIAT, V202, P212, DOI 10.1192/bjp.bp.112.113548
  25. Kjaerstad H.L., 2022, J AFFECT DISORDERS
  26. Kjaerstad HL, 2016, PSYCHIAT RES, V238, P318, DOI 10.1016/j.psychres.2016.02.047
  27. Kjaerstad HL, 2022, EUR NEUROPSYCHOPHARM, V60, P7, DOI 10.1016/j.euroneuro.2022.04.010
  28. Kjaerstad HL, 2021, PSYCHOL MED, V51, P668, DOI 10.1017/S0033291719003738
  29. Kjaerstad HL, 2020, PSYCHOL MED, V50, P1808, DOI 10.1017/S0033291719001867
  30. Lahera G, 2013, J AFFECT DISORDERS, V146, P132, DOI 10.1016/j.jad.2012.06.032
  31. Martinez-Aran A, 2007, BIPOLAR DISORD, V9, P103, DOI 10.1111/j.1399-5618.2007.00327.x
  32. Michalak Erin E, 2005, Health Qual Life Outcomes, V3, P72, DOI 10.1186/1477-7525-3-72
  33. Miskowiak KW, 2018, ACTA PSYCHIAT SCAND, V138, P336, DOI 10.1111/acps.12915
  34. Miskowiak KW, 2019, BIPOLAR DISORD, V21, P686, DOI 10.1111/bdi.12834
  35. Miskowiak KW, 2021, EUR NEUROPSYCHOPHARM, V46, P37, DOI 10.1016/j.euroneuro.2021.03.017
  36. Murphy SE, 2008, PSYCHOPHARMACOLOGY, V199, P503, DOI 10.1007/s00213-008-1082-2
  37. NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5
  38. Organization W.H, 1992, ICD 10 CLASS MENT BE
  39. Ospina LH, 2018, J AFFECT DISORDERS, V235, P7, DOI 10.1016/j.jad.2018.03.013
  40. Ossola P, 2020, ELIFE, V9, DOI 10.7554/eLife.58891
  41. Painter JM, 2019, GEN HOSP PSYCHIAT, V61, P96, DOI 10.1016/j.genhosppsych.2019.07.013
  42. Passos IC, 2016, ACTA PSYCHIAT SCAND, V134, P91, DOI 10.1111/acps.12581
  43. Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823
  44. Rey A., 1958, CLIN EXAMINATION PSY
  45. Rosa Adriane R, 2007, Clin Pract Epidemiol Ment Health, V3, P5, DOI 10.1186/1745-0179-3-5
  46. Russo M, 2017, PSYCHOL MED, V47, P2892, DOI 10.1017/S003329171700143X
  47. Sanchez-Moreno J, 2018, ACTA PSYCHIAT SCAND, V138, P145, DOI 10.1111/acps.12894
  48. Serafini G, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11020276
  49. Stafford N, 2013, ACTA PSYCHIAT SCAND, V127, P11, DOI 10.1111/acps.12118
  50. Szmulewicz A, 2020, J AFFECT DISORDERS, V266, P194, DOI 10.1016/j.jad.2020.01.082
  51. Tranter R, 2009, J AFFECT DISORDERS, V118, P87, DOI 10.1016/j.jad.2009.01.028
  52. Van Dijk S, 2013, J AFFECT DISORDERS, V145, P386, DOI 10.1016/j.jad.2012.05.054
  53. Varo C, 2022, PSYCHOL MED, V52, P159, DOI 10.1017/S0033291720001865
  54. Varo C, 2021, EUR NEUROPSYCHOPHARM, V51, P71, DOI 10.1016/j.euroneuro.2021.05.003
  55. WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589
  56. Wingo AP, 2009, J CLIN PSYCHIAT, V70, P1588, DOI 10.4088/JCP.08r04972
  57. Wium-Andersen IK, 2017, NORD J PSYCHIAT, V71, P12, DOI 10.1080/08039488.2016.1216163
  58. Yim O, 2015, QUANT METH PSYCHOL, V11, P8, DOI 10.20982/tqmp.11.1.p008
  59. YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429
  60. Zhang Y, 2019, PSYCHIAT RES, V274, P377, DOI 10.1016/j.psychres.2019.03.002

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/21